#BEGIN_DRUGCARD DB03659

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
109-73-9

# ChEBI_ID:
43799

# Chemical_Formula:
C4H11N

# Chemical_IUPAC_Name:
butan-1-amine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Butylamine is an organic compound, specifically, an amine. This colourless liquid is one of the four isomeric amines of butane, the others being sec-butylamine, tert-butylamine and isobutylamine. At standard temperature and pressure, n-butylamine is a liquid having the fishy, ammonia-like odor common to amines. The liquid acquires a yellow colour upon storage in air. It is soluble in all organic solvents. [Wikipedia]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.97

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Butylamine

# HET_ID:
LYT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H11N/c1-2-3-4-5/h2-5H2,1H3

# InChI_Key:
InChIKey=HQABUPZFAYXKJW-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3659

# Mechanism_Of_Action:
Not Available

# Melting_Point:
-49.1 °C

# Molecular_Weight_Avg:
73.1368

# Molecular_Weight_Mono:
73.089149357

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EAG

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.85

# Predicted_LogS:
0.04

# Predicted_Water_Solubility:
8.07e+01 g/l

# Primary_Accession_No:
DB03659

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
8007

# PubChem_Substance_ID:
46508030

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02080

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCN

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
1-aminobutane
1-butanamine
n-butylamine

# Synthesis_Reference:
Not Available

# Toxicity:
Oral rat LD<sub>50</sub> is 366 mg/kg.

# Update_Date:
2013-02-08 16:22:29 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/N-Butylamine

# pKa_Isoelectric_Point:
10.8 (at 20 °C)

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M83663

# Drug_Target_1_GenBank_ID_Protein:
170841

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
SAP2

# Drug_Target_1_Gene_Sequence:
>1197 bp
ATGTTTTTAAAGAATATTTTCATTGCTCTTGCTATTGCTTTATTAGTCGATGCTACTCCA
ACAACAACCAAAAGATCAGCTGGTTTCGTTGCTTTAGATTTCAGTGTTGTGAAAACTCCT
AAAGCATTCCCAGTTACTAATGGTCAAGAAGGTAAAACTTCCAAAAGACAAGCTGTCCCA
GTGACTTTACACAATGAACAAGTCACTTATGCTGCTGATATTACCGTTGGATCCAATAAT
CAAAAACTTAATGTTATTGTTGATACTGGATCATCTGATTTATGGGTTCCTGATGTTAAT
GTTGATTGTCAAGTCACTTATAGTGATCAAACTGCAGATTTCTGTAAACAAAAGGGGACA
TATGATCCAAGTGGTTCATCAGCTTCACAAGATTTGAATACTCCATTCAAAATTGGTTAT
GGTGATGGATCTTCATCTCAAGGTACTTTATATAAGGATACCGTTGGATTTGGTGGTGTT
TCGATTAAAAATCAAGTTTTAGCTGATGTTGATTCTACTTCAATTGATCAAGGTATTTTA
GGAGTTGGTTATAAAACCAATGAAGCCGGTGGTAGTTATGATAATGTCCCTGTCACTTTA
AAAAAACAAGGAGTCATTGCTAAGAATGCTTATTCACTTTATCTTAATTCTCCAGATGCT
GCCACGGGACAAATAATTTTCGGTGGGGTTGATAATGCTAAATATAGTGGTTCATTAATT
GCATTACCAGTTACTTCTGATCGTGAATTAAGAATTAGTTTGGGTTCAGTTGAAGTTTCT
GGTAAAACCATCAATACTGATAATGTCGATGTTCTTTTGGATTCAGGTACCACCATTACT
TATTTGCAACAAGATCTTGCTGATCAAATCATTAAAGCTTTCAATGGTAAATTAACTCAA
GATTCCAATGGTAATTCATTCTATGAAGTTGATTGTAATTTGTCAGGGGATGTTGTATTC
AATTTTAGTAAAAATGCTAAAATTTCCGTTCCAGCTTCCGAATTTGCTGCTTCTTTACAA
GGTGATGATGGTCAACCATATGATAAATGTCAATTACTTTTCGATGTTAATGATGCTAAC
ATTCTTGGTGATAACTTTTTGAGATCAGCTTATATTGTTTATGATTTGGATGATAATGAA
ATTTCTTTGGCTCAAGTCAAATATACTTCTGCTTCCAGTATTTCTGCCTTGACCTAA

# Drug_Target_1_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_1_General_References:
1447155	Wright RJ, Carne A, Hieber AD, Lamont IL, Emerson GW, Sullivan PA: A second gene for a secreted aspartate proteinase in Candida albicans. J Bacteriol. 1992 Dec;174(23):7848-53.
1491622	Mukai H, Takeda O, Asada K, Kato I, Murayama SY, Yamaguchi H: cDNA cloning of an aspartic proteinase secreted by Candida albicans. Microbiol Immunol. 1992;36(11):1207-16.
8407785	White TC, Miyasaki SH, Agabian N: Three distinct secreted aspartyl proteinases in Candida albicans. J Bacteriol. 1993 Oct;175(19):6126-33.
8591036	Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, Cutfield JF: The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure. 1995 Nov 15;3(11):1261-71.
9043112	Smolenski G, Sullivan PA, Cutfield SM, Cutfield JF: Analysis of secreted aspartic proteinases from Candida albicans: purification and characterization of individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology. 1997 Feb;143 ( Pt 2):349-56.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3180

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
42330

# Drug_Target_1_Name:
Candidapepsin-2

# Drug_Target_1_Number_of_Residues:
398

# Drug_Target_1_PDB_ID:
1EAG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00026	Asp

# Drug_Target_1_Protein_Sequence:
>Candidapepsin-2 precursor
MFLKNIFIALAIALLVDATPTTTKRSAGFVALDFSVVKTPKAFPVTNGQEGKTSKRQAVP
VTLHNEQVTYAADITVGSNNQKLNVIVDTGSSDLWVPDVNVDCQVTYSDQTADFCKQKGT
YDPSGSSASQDLNTPFKIGYGDGSSSQGTLYKDTVGFGGVSIKNQVLADVDSTSIDQGIL
GVGYKTNEAGGSYDNVPVTLKKQGVIAKNAYSLYLNSPDAATGQIIFGGVDNAKYSGSLI
ALPVTSDRELRISLGSVEVSGKTINTDNVDVLLDSGTTITYLQQDLADQIIKAFNGKLTQ
DSNGNSFYEVDCNLSGDVVFNFSKNAKISVPASEFAASLQGDDGQPYDKCQLLFDVNDAN
ILGDNFLRSAYIVYDLDDNEISLAQVKYTSASSISALT

# Drug_Target_1_Reaction:
Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave Leu15-Tyr, Tyr16-Leu and Phe24-Phe of insulin B chain. Activates trypsinogen, and degrades keratin INHIBITOR Pepstatin

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave 15-Leu-|-Tyr-16, 16- Tyr-|-Leu-17 and 24-Phe-|-Phe-25 of insulin B chain. Activates trypsinogen, and degrades keratin

# Drug_Target_1_SwissProt_ID:
P28871

# Drug_Target_1_SwissProt_Name:
CARP2_CANAL

# Drug_Target_1_Synonyms:
ACP 2
Aspartate protease 2
Candidapepsin-2 precursor
EC 3.4.23.24
Secreted aspartic protease 2

# Drug_Target_1_Theoretical_pI:
4.25

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB03659
